Insmed Inc
Company Profile
Business description
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Contact
700 US Highway 202/206
BridgewaterNJ08807
USAT: +1 908 977-9900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,664
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,823.90 | 11.70 | 0.13% |
| CAC 40 | 7,987.49 | 0.00 | 0.00% |
| DAX 40 | 24,307.92 | 357.35 | 1.49% |
| Dow JONES (US) | 49,686.12 | 159.95 | 0.32% |
| FTSE 100 | 10,323.75 | 128.38 | 1.26% |
| HKSE | 25,749.12 | 73.94 | 0.29% |
| NASDAQ | 26,090.73 | 134.41 | -0.51% |
| Nikkei 225 | 60,677.08 | 138.87 | -0.23% |
| NZX 50 Index | 12,912.36 | 149.44 | 1.17% |
| S&P 500 | 7,403.05 | 5.45 | -0.07% |
| S&P/ASX 200 | 8,601.40 | 19.80 | 0.23% |
| SSE Composite Index | 4,132.46 | 0.93 | 0.02% |